Peter van Mourik

197 General discussion 16. Vijftigschild, L. A. W. et al. β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis. Eur. Respir. J. 48 , 768–79 (2016). 17. Sato, T. et al. Single Lgr5 stem cells build crypt – villus structures in vitro without a mesenchymal niche. Nature 459 , 262–265 (2009). 18. Trezíse, A. E. O. & Buchwald, M. In vivo cell-specific expression of the cystic fibrosis transmembrane conductance regulator. Nature 353 , 434–437 (1991). 19. Hogan, B. L. M. et al. Repair and Regeneration of the Respiratory System: Complexity, Plasticity, and Mechanisms of Lung Stem Cell Function. Cell Stem Cell 15 , 123–138 (2014). 20. Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141 , 1762–72 (2011). 21. Sachs, N. et al. Long-term expanding human airway organoids for disease modeling. EMBO J. 38 , e100300 (2019). 22. Lin, H. et al. Air-Liquid Interface (ALI) Culture of Human Bronchial Epithelial Cell Monolayers as an in vitro Model for Airway Drug Transport Studies. J. Pharm. Sci. 96 , 341–350 (2007). 23. Frank J. Accurso,, Steven M. Rowe, J.P. Clancy, Michael P. Boyle., Jordan M. Dunitz, Peter R. Durie, Scott D. Sagel, Douglas B. Hornick, M. W. K., Scott H. Donaldson, Richard B. Moss, Joseph M. Pilewski, Ronald C. Rubenstein, Ahmet Z. Uluer, Moira L. Aitken, Steven D. Freedman, L. M. R. & Nicole Mayer- Hamblett, Qunming Dong, Jiuhong Zha, Anne J. Stone, Eric R. Olson, Claudia L. Ordoñez, Preston W. Campbell, Melissa A. Ashlock, and B. W. R. Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation. October 363 , 339–354 (2010). 24. Barry, P. J. et al. Eff ects of Ivacaft or in Patients with Cystic Fibrosis Who Carry the G551D mutation and have severe lung disease. Chest 146 , 152–158 (2014). 25. Ramsey, B. W. et al. A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. N. Engl. J. Med. 365 , 1663–1672 (2011). 26. Graeber, S. Y. et al. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. Am. J. Respir. Crit. Care Med. 192 , 1252–5 (2015). 27. Mesbahi, M. et al. Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor. J. Cyst. Fibros. 16 , 45–48 (2016). 28. Flume, P. A. et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142 , 718–724 (2012). 29. Farinha, C. M. & Canato, S. From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking. Cell. Mol. Life Sci. 74 , 39–55 (2017). 30. Clancy, J. P. et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67 , 12–18 (2012). 9